Mumbai-based Wockhardt ?s second production facility was recently placed under an import ban. Ranbaxy?s three production units have also been placed under import ban due to violations in manufacturing practices. In May 2013, the company also pleaded guilty and paid $500 million as penalty to charges of various manufacturing violations and making misstatements. However, USFDA warnings issued to US-based units of Indian companies have not yet translated to an import ban later. Sun Pharmaceutical Industries? subsidiary Caraco Pharmaceutical Laboratories and Ranbaxy?s Ohm Laboratories, both based in the US, had received warning letters in 2009. However, violations identified in both the cases were later resolved, without any further action. Jubilant posted consolidated sales of Rs 1,436 crore in Q2FY14, which represented a 17% year-on-year growth. Its Ebitda for the same period fell 1% y-o-y to Rs 276 crore. Its consolidated FY13 revenue of Rs 5,161 crore, saw a growth of 21% from FY12.